Table Of Content

Contraception 1999:59:405-406 ELSEVIER Author Index Volume 59 January-June 1999 Affandi, B., 167 Dhar, J.D., 401 Imhof, M., 287 Ajani, U., 181 Diadhiou, F., 377 Isokoski, M., 257 Akers, R., 195 Dieben, T.O.M., 59 Alvarez, F., 245, 31 Dunson, R., 377 Amer, N.A., 395 Dunson, T.R., 245 Jackanicz, T.M., 305 Anjalika, 67 Dwivedi, A.K., 401 Jaisamrarn, U., 301 Archer, D.F., 175 Jensen, J.T., 153 Astley, S.J., 153 Jeyaraj, D.A., 333 Athayde, C., 115 Egarter, C., 287 Jick, H., 79 Aydemir, V., 389 Eisinger, S.H., 1 Jick, S.S., 79 El Houssinie, M., 369 Jones, K.P., 17S Ellertson, 107, 147, 2 Ba, M.G., 377 El Nahal, N., 369 Bajaj, J.S., 333 Elul, B., ee Karanja, J.G., 253 Baker, J.M., 175 Esteve, J.L.L.C., 11, 219 Katz, D.F., 91 Barbosa, I., 115 Kaunitz, A.M., 29 S Bilekli, C., 389 Kigondu, C.S., 25: 3 Blackwell, R 195 Fan, S., Kirkkola, A., 257 “ec "a 245 Blanchard, K. 209 Korver, T., 167 Blumenthal, P.D., 245 Fauser, B.C.]. es 237 Kouedou, D., 37 Flamigni, C., 29. Bonacho, I., 233 Kuhn, L., 363 Bozkaya, H., 389 Fonck, K., 253 Franks, P., 1 Brache, V., 245, 311 Burkhart, M.C., 271 Frascaro, M., 22 1, 93 Lacarra, M., 305 Fraser, I.S., 123, 305, 311 Lawson, L., 195 Fuschini, G.. ¢3 —— C., 293 Cabezas, E., 219 Camacho-Arroyo, I., 339 li, B. canes J., 161 Carbonell, J.L.L., 11, 219 Gammi, L., 293 Cerbon, M.A., 339 Ganguly, N.K., 67 Loffer, F., 187 Chai, D., 131 Garcia, G.A., 339 Lohiya, N.K., 137 Chapin, R.E., 203 Gentzschein, E., 17 LONG, 31 Chen, C., 319 Geurts, T.B.P., 167 Lotufo, P.A., 181 Chen, J., 85 Gharaibeh, M.N., 395 Lowrance, J.L., 47 Coccheri, S., 293 Gichangi, P.B., 253 Cochon, L., 245 Glasier, A., 71 Macaluso, M., 195 Coelingh Bennink, H.J.T., 167 Godwin, A., 161 Maikhuri, J.P., 401 Colli, E., 227 Gola, G., 293 Makokha, A., 131 Connell, E.B., 7S Gomez-Besteiro, M.I., 233 Manivannan, B., 137 Coutinho, E.M., 115 Gore, B.Z., 1 Manson, J.A.E., 181 Coyaji, K., 107 Grubb, G.S., 187 Markham, R., 1 Creinin, M.D., 11, 383 Gupta, G., 401 Massaro, J., 161 Gupta, I., 67 Mattila, K., 2 Gupta, S.K., 67 Dantas, C., 115 Mazariegos, L., 271 Darney, P., 305 Mendoza-Rodriguez, C.A., 339 Daw, B.,.377 Hammond, K., 195 Miller, W.C., 97 Davis, A., 39S Hassan, E.O., 369 Mishell, D.R., Jr, 5S, 17, 21S, B’Cruz, O:f., 319 dennekens, C.H., 181 305 Delaney, J.C., 203 Hess, T., 271 Mishell, D.R., Jr., 311 DelConte, A., 187 Hickey, M., 123 Mishra, P.K., 137 Denny, L., 363 Hirsch. C., 115 Moreau, LC. 377 den Tonkelaar, I., 357 Hoe; Sie, 85 Morgan, E., 153 DeSoto, K.R., 175 Hortin, G., 195 Morrison, C.S., 9 Development, S.P.R., 31 Huber, J., 287 Mwethera, P.G., 131 © 1999 Elsevier Science Inc. All rights reserved 655 Avenueo f the Americas, New York NY 10010 406 Author index Contraception 1999;59:405-406 Nash, H.A., 311 Schwartz, J.L., 11, 383 (UNFPA)/World Health Nichols, M.D., 153 Sekadde-Kigondu, C., 97 Organization (WHO)/World Niruthisard, S., 63 Setty, B.S., 401 Bank (WB), Special Sharma, R.S., 333 Programme of Research, Oddens, B.J., 277, 357 Shomaf, M.S., 395 Development and Research Okuda, H., 203 Simbar, M., 123 Training in Human Oral Contraceptive and Sinei, S:.K., 97 Reproduction, Task Force on Hemostasis Study Group, Siu, C., 161 Long-acting Systemic Agents 345 Smith, S.R., 47 for Fertility Regulation, 31 Owen, D.H., 91 Sokal, D., 377 Ozeren, M., 389 Sokol, R.Z., 203 Valappil, T., 195 Spelsberg, A., 181 van Heusden, A.M., 237 Palareti, G., 293 Stadalius, L.S., 1 Varela, L., 11, 219 Parazzini, F., 227 Stanczyk, F.Z., 17, 203 Vasilakis, C., 79 Penhallegon, R., 227 Sulak, P., 161 Velazco, A., 219 Pita, S., 233 Sulak, P.J., 35S Vino, L, 257 Ploszaj, S., 17 Suwajanakon, S., 63 Pollack, A.E., 363 Waurzyniak, B., 319 Poppema, S., 1 Tanda, R., 11, 219 Weaver, K., 71 Pymar, H.C., 383 Taneepanichskul, S., 63, 301 Weiner, D.H., 97 Tang, G., 25 Weisberg, E., 305, 311 Qian, D., 17 Tang, OS., 25 Westhoff, C.L., 5S, 25S Temmerman, M., 253 Wiebe, E.R., 7, 265 Rajalakshmi, M., 333 Tessarotto, L.A.B., 47 Winikoff, B., 107, 209 Reinprayoon, D., 63, 301 Tong, D., 227 Wolfe, G.W., 203 Ridker, P.M., 181 Topcuoglu, M.A., 287 Wright, T.C., 363 Rodriguez, G., 147 Trussell, J., 147 Wysocki, S., 39S Roumen, F.J.M.E., 59 Tyagi, A., 333 Russell, P., 123 Tyrer, L.B., 115 Yip, P.25 Salazar, S., 271 Uckun, F.M., 319 Yiv, S.H., 319 Salhab, A.S., 395 United Nations Development Young, L., 123 Sanchez, C., 219 Programme (UNDP)/United Schaff, E.A., 1 Nations Population Fund Zhu, Z.,-319 Contraception 1999:59:407-—409 ELSEVIER Subject Index Volume 59 January-June 1999 Acceptability, Contraception in the prepill era, 75 Cyclofem®, 383 Contraceptive discontinuations, 227 Mesigyna®, 383 Contraceptive methods, knowledge sources, 257 nonmedicated vaginal ring, 59 Contraceptive status, climacteric women, 85 Activated protein C resistance screening, before OC Contraceptive vaginal ring (CVR), releasing ethinyl treatment, 293 estradiol + norethindrone acetate, 305, 311 Anti-HIV activity, WHI-05, 319 Copper IUD users, Antibiotics, interaction with OC pill, 71 level of reactive nitrogen intermediates, 67 level of reactive oxygen intermediates, 67 Copper IUDs, effect on lipid metabolism, 31 Benefits, OC use, 39S Cu-Fix IUD, effect on endometrium, 63 Birth control, women’s satisfaction, 277 Current use and attitudes, oral contraception, 17S Bleeding patterns, use of ethinyl estradiol + CVR (contraceptive vaginal ring) norethindrone acetate, CVR, 311 Cycle control, Blood pressure, ethinyl estradiol + levonorgestrel, 187 effect of DMPA, 301 ethinyl estradiol + norethindrone acetate, 187 effect of TCu 380A, 301 Cyclofem®, acceptability, 383 Bone mineral density, effect of DMPA, 25 Breast cancer risk, OC use, 25S Breastfeeding, effect of elcometrine, 115 Depot-medroxyprogesterone acetate (DMPA), discontinuation, 227 effect on bone mineral density, 25 c-fos mRNA content, effect of effect on cervical epithelium, 363 norethisterone/metabolites (rat), 339 effect on weight and blood pressure, 301 Carbohydrate metabolism, effect of testosterone Discontinuations, contraceptives, 227 enanthate (monkey), 333 Cardiovascular disease risk, effect of vasectomy, DMPA (depot-medroxyprogesterone acetate), 301 Drug interactions, OC pill and antibiotics, 71 18] Cardiovascular risks, OC use, 21S Castor bean extract, Effectiveness, Yuzpe regimen of emergency effect on implantation (rabbit), 401 contraception, 147 effect on ovulation (rabbit), 401 Efficacy, CDRI 84/35, effect on daily sperm production (rat}, ethinyl estradiol + norethindrone acetate CVR, 401 31] Cervical epithelium, effect of DMPA, 363 Implanon, 167 Climacteric women, Yuzpe regimen of emergency contraception, 147 contraceptive status, 85 Elcometrine (ST-1435), sexual function, 85 effect on breastfeeding, 115 Clinical evaluation, Norplant implants, 389 implant contraceptive, 115 Clinical study, Emergency contraception, ethinyl estradiol + norethindrone acetate, 161 ethinyl estradiol + levonorgestrel, 14 = ethinyl estradiol + norethindrone acetate CVR, level of knowledge, 253 305, 311 risk of venous thromboembolism, 79 Implanon implant, 167 Yuzpe method, 147 Norplant implants, 389 Endometrial microvascular density, Norplant triphasic ethinyl estradiol + norgestimate, 161 implants users, 123 Clinician/patient interaction, OC use, 39S Endometrium, Comparative study protocol, OC and hemostasis, effect of Cu-Fix IUD orf effect of levonorgestrel, 123 Condom failure, prostrate-specific antigen level in Estradiol, effect on daily sperm production (rat), 345 vagina fluid, 195 Ethinyl estradiol + desogestsrel, Condoms, ovarian activity during pill-free interval, 237 optical testing, 47 quality-of-life benefits, 287 women’s satisfaction, 277 user satisfaction, 287 © 1999 Elsevier Science Inc. All rights reserved ISSN 0010-7824/99/$20.00 655 Avenue of the Americas, New York, NY 10010 Pll SO010-7824(99)00000-C 408 Subject Index Contraception 1999:59:407-—409 Ethinyl estradiol + gestodene, ovarian activity effect on endometrium, 123 during pill-free interval, 237 effect on lipid metabolism, 31 Ethinyl estradiol + levonorgestrel, effect on cycle effect on ovarian function, 245 control, 187 Levonorgestrel implants, pop-out method of Ethinyl estradiol + norethindrone acetate, removal, 369 clinical study, 161 Lipid metabolism, effect on cycle control, 187 effect of copper IUDs, 31 Ethinyl estradiol + norethindrone acetate CVR, effect of levonorgestsrel, 31 clinical study, 305, 311 Ethinyl estradiol + norgestimate, clinical study, 161 Mechanism of action, Ethylene-vinyl-acetate copolymer, vaginal ring, 59 copper IUDs, 67 progesterone-releasing IUD, 175 Fertilin 8 protein, effect on fertilization (baboon), Medical abortion, 131 methotrexate, 7, 395 Fertilizaton, effect of fertiliin B protein (baboon), methotrexate + misoprostol, 7, 11, 265, 395 131 mifepristone + misoprostol, 1, 107, 153 Fluid medium, vaginal fluid simulant, 91 misoprostol, 209, 219 tamoxifen + misoprostol, 265 Glucose metabolism, effect of testosterone Menstrual bleeding, enanthate (monkey), 333 hormone replacement therapy, 357 OC use, 357 Health benefits, OC use, 29S relation to reproductive status, 357 Hemostataic variables, effects of OC regimens Menstrual cycles, incidence of irregular cycles, 271 (study protocol), 377 Mesigyna®, acceptability, 395 Hormone replacement therapy, bleeding patterns, Methotrexate, medical abortion, 7, 395 357 Methotrexate + misoprostol, medical abortion, 7, 11, 265, 395 Impact, introduction of the birth control pill, 11S Mifepristone + mispoprostol, Implanon® implant, clinical study, 167 medical abortion, 1 Implant contraceptive, outcomes of procedure, 153 side effects, 107 elcometrine (ST-1435), 115 etonogestrel, 167 Misoprostol, medical abortion, 209, 219, 395 levonorgestrel, 31, 123, 245, 369, 389 Implantation, Natural contraceptive methods, effect of irregular effect of castor bean extract (rabbit), 401 cycles, 271 effect of ricin A-chain (rabbit), 401 Natural family planning, women’s satisfaction, 277 Injectable contraceptive, Nonmedicated vaginal ring, 59 depot-medroxyprogesterone acetate, 25, 301, 363 Norethisterone/metabolites, DMPA + estradiol cypionate, 383 effet on uterine c-fos mRNA content (rat), 339 norethisterone enanthate + estradiol valerate, 383 effect on uterine progesterone receptor (rat), 339 Interleukin-6 level, effect of progesterone-releasing Normative reproductive indices, adult Sprague- IUD, 175 Dawley rats, 203 Intrauterine device (IUD), Norplant® implants, Cu-Fix, 63 clinical evaluation, 389 discontinuations, 227 effect on endometrium, 123 progesterone-releasing, 175 effect on lipid metabolism, 31 TCu 380A, 115, 233, 301 onset of contraceptive effect, 245 user satisfaction pop-out method of removal, 369 Introduction of the birth control pill and its impact, 11S OC (oral contraceptive) Irregular cycles, implications for fertility awareness OC regimens, effects of hemostatic variables (study methods, 271 protocol), 377 IUD candidates, STD risk assessment, 97 OC use, bleeding patterns, 357 Knowledge, attitudes and practice of emergency breast cancer risk, 25S contraception, 253 cardiovascular risks, 21S Knowledge sources, contraceptive methods, 257 clinician/patient interaction, 39S effect of smoking, 17 Levonorgestrel, health benefits, 29S Contraception Subject Index 409 1999;59:407-409 Onset of contraceptive effectiveness, Norplant Side effects, implants, 245 mfepristone + misoprostol abortion, 107 Optical testing, condoms, 47 srgical abortion, 107 Oral contraceptive (OC), use of ehinyl estradiol + norethindrone acetate CVR, 311 current use and attitudes, 17S discontinuations, 227 Smoking, effect of OC use, 17 ethinyl estradiol + desogestrel, 237, 287 Sperm production, ethinyl estradiol + gestodene, 237 effect of CDRI 84/35 (rat), 345 ethinyl estradiol + levonorgestrel, 187 effect of estradiol (rat), 345 ethinyl estradiol + norethindrone acetate, 17, Spermicidal activity, WHI-05, 319 161, 187 Sprague-Dawley rats, normative reproductive ethinyl estradiol + norgestimate, 161 indices, 203 interaction with antibiotics, 71 STD (sexually transmitted diseases) quality-of-life benefits, 35S STD risk assessment, IUD candidates, 97 therapeutic uses, 35S Sterilization, women’s satisfaction, 277 thrombophilic screening before use, 293 Styrene maleic anhydride, effect on vas deferens user satisfaction, 277 (monkey) 137 Ovarian activity, Suction curettage abortion, outcomes of procedure, effect of Norplant implants, 245 153 pill-free period during OC use, 237 Surgical abortion, side effects, 107 Ovulation, effect of castor bean extract (rabbit), 395 Tamoxifen + misoprostol, medical abortion, 265 effect of ricin A-chain (rabbit), 401 TCu 380A, effect on breastfeeding, 115 Pop-out method of removal, levonorgestrel effect on weight and blood pressure, 301 implants, 369 long-term users, 223 Postcoital contraceptive pills, risk of venous Therapeutic uses, oral contraceptives, 35S thromboembolism, 79 Thrombophilic screening, before OC treatment, 293 Preferences, menstrual bleeding frequency, 357 Thromboxane A, levels, effect of ethinyl estradiol + Prepill era, methods of contraception, 75 norethindrone acetate, 17 Progesterone receptor, effect of Triphasic ethinyl estradiol + norgestimate, clinical norethisterone/metabolites (rat), 339 study, 161 Progesterone-releasing IUD, possible mechanism of Tumor necrosis factor-a level, effect of action, 175 progesterone-releasing IUD, 175 Prostacyclin levels, effect of ethinyl estradiol + norethindrone acetate, 17 Vaginal fluid simulant, 91 Prostate-specific antigen in vaginal fluid, biologic Vaginal ring, made of ethylene-vinyl-acetate marker of condom failure, 195 copolymer, 59 Vas deferens, effect of styrene maleic anhydride Quality-of-life benefits, (monkey), 137 effect of ethinyl estradiol + desogestrel, 287 Vas occlusion, styrene maleic anhydride (monkey), oral contraceptives, 35S 137 Vasectomy, risk of cardiovascular disease, 181 Reactive nitrogen intermediates, effect of copper Venous thromboembolism risk, postcoital IUDs, 67 contraceptive pill use, 79 Reactive oxygen intermediates, effect of copper IUDs, 67 Weight, Removal of levonorgestrel implants, pop-out effect of DMPA, 301 method, 369 effect of TCu 380A, 301 Reproductive indices (rat), 203 WHI-05, Reproductive status, characteristics of menstrual spermicidal activity, 319 bleeding, 357 anti-HIV activity, 319 Ricin A-chain, zidovudine derivative, 319 effect on implantation (rabbit), 401 effect of ricin A-chain (rabbit), 401 Yuzpe regimen, Risks, OC use, 39S emergency contraception, 147 estimates of effectiveness, 147 Satisfaction with birth control, 277 Sexual function, climacteric women, 85 Zidovudine derivative, WHI-05, 389